Literature DB >> 16794561

Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward.

Faïza Benaliouad1, Shitij Kapur, Pierre-Paul Rompré.   

Abstract

Previous studies have shown that effective antipsychotic medications attenuate reward, an effect that is generally attributed to their effectiveness at blocking the dopamine D2-like receptors. As blockade of the serotonin type 2a (5-HT2a) receptors is a common property of the newer antipsychotics, the present study compared the effect of haloperidol, clozapine, and M100907 (a selective 5-HT2a antagonist) and the combined effect of haloperidol and M100907 treatment on brain stimulation reward (BSR). Experiments were performed on male Sprague-Dawley rats trained to produce an operant response to obtain electrical stimulation in the lateral hypothalamus. Measures of reward threshold were determined in different groups of rats using the curve-shift method using fixed current intensity and variable frequency before and at different times after injection of haloperidol (0.01, 0.05, 0.1, and 0.25 mg/kg), clozapine (1, 7.5, 15, and 30 mg/kg), M100907 (0.033, 0.1, and 0.3 mg/kg), or their vehicle. The effect of M100907 (0.3 mg/kg) on the attenuation of BSR by a sub- and suprathreshold dose of haloperidol was studied in another group of rats. Clozapine produced a dose-orderly increase in reward threshold with a mean maximal increase of 50%; at high doses, clozapine induced cessation of responding in several animals at different time periods. Haloperidol induced a dose-dependent increase in reward threshold, with the mean maximal increase (75%) being observed at the highest dose; it also produced a dose-dependent reduction of maximum rates of responding. M100907 failed to alter reward at any of the doses tested and had no effect on the subthreshold dose (0.01 mg/kg) of haloperidol. But when combined with a suprathreshold dose of haloperidol, M100907 reduced the reward-attenuating effect of haloperidol. These results show that 5-HT2a receptors are unlikely to constitute a component of the reward-relevant pathway activated by lateral hypothalamic stimulation. However, blockade of 5-HT2a receptors may account for the relatively lower level of reward attenuation produced by clozapine, and predict that antipsychotic medications that have a high affinity for the 5-HT2a receptor may be less likely to induce dysphoria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794561     DOI: 10.1038/sj.npp.1301136

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  15 in total

1.  Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning.

Authors:  Ming Li; Tao Sun; Chen Zhang; Gang Hu
Journal:  Psychopharmacology (Berl)       Date:  2010-07-10       Impact factor: 4.530

Review 2.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

3.  Role of serotonin 5-HT2A and 5-HT2C receptors on brain stimulation reward and the reward-facilitating effect of cocaine.

Authors:  Vicky Katsidoni; Kalliopi Apazoglou; George Panagis
Journal:  Psychopharmacology (Berl)       Date:  2010-06-25       Impact factor: 4.530

4.  Clozapine increases reward evaluation but not overall ingestive behaviour in rats licking for sucrose.

Authors:  Adriana Galistu; Cristina Modde; Maria Cristina Pireddu; Flavia Franconi; Gino Serra; Paolo S D'Aquila
Journal:  Psychopharmacology (Berl)       Date:  2011-03-01       Impact factor: 4.530

5.  5-HT2A receptors modulate dopamine D2-mediated maternal effects.

Authors:  Jun Gao; Leilei Chen; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2019-03-21       Impact factor: 3.533

6.  Qualitative differences between C57BL/6J and DBA/2J mice in morphine potentiation of brain stimulation reward and intravenous self-administration.

Authors:  Greg I Elmer; Jeanne O Pieper; Lindsey R Hamilton; Roy A Wise
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

7.  Open-label pilot study of quetiapine treatment for cannabis dependence.

Authors:  John J Mariani; Martina Pavlicova; Agnieszka K Mamczur; Adam Bisaga; Edward V Nunes; Frances R Levin
Journal:  Am J Drug Alcohol Abuse       Date:  2014-07       Impact factor: 3.829

8.  Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats.

Authors:  Tracie A Paine; William A Carlezon
Journal:  Neuropharmacology       Date:  2009-03       Impact factor: 5.250

9.  Preclinical Abuse Potential Assessment of Flibanserin: Effects on Intracranial Self-Stimulation in Female and Male Rats.

Authors:  Matthew F Lazenka; Bruce E Blough; S Stevens Negus
Journal:  J Sex Med       Date:  2016-01-28       Impact factor: 3.802

10.  Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio.

Authors:  Somayeh Jafari; Marc E Bouillon; Xu-Feng Huang; Stephen G Pyne; Francesca Fernandez-Enright
Journal:  BMC Pharmacol       Date:  2012-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.